Niki BioSolutions, Inc. (NIKI) · Oct 9, 2026 · Share issuance

Niki BioSolutions ATM financing opens $1.396M dilution line

$1.396M ATM financing — up to $1.396M in common-stock sales; 3.0% placement fee

Niki BioSolutions launches a $1.396 million ATM financing program, giving its cash-strapped post-merger biotech flexibility but adding dilution risk.

Niki BioSolutions is a newly merged, clinical-stage life-sciences company combining DiamiR’s genomic and biomarker-testing platform with Aptorum’s legacy biotech assets; its latest financials show limited operating history, recurring losses, and substantial doubt about continued operations without new financing.

The filing creates a usable but small funding valve. Niki can sell up to $1.396 million of common stock through an at-the-market program, with no obligation to sell and no guaranteed proceeds. 〔0〕 That is meaningful relative to the company’s June 30 cash balance of $1.83 million and six-month operating cash burn of $1.55 million, but it is not a full solution to the funding gap.

The immediate business effect is liquidity support, not operating progress. The proceeds could help keep the post-merger platform and laboratory operations moving, but the filing contains no new clinical, commercial, or revenue milestone. Because the shares are sold at market prices, the program also leaves shareholders exposed to dilution as capital is raised; the company will pay Wainwright a 3.0% placement fee on agent sales. 〔1〕

The related-party structure adds governance friction. Niki’s largest shareholder and a director, Dr. Kira Sheinerman, is a managing director of Wainwright, so the offering requires FINRA conflict-of-interest procedures and Brookline’s participation as an independent qualified underwriter. That does not block the financing, but it makes the capital raise less straightforward than a routine ATM.

Bottom line: This is a necessary financing tool for a company whose liquidity was already under pressure, but it advances funding—not the underlying biotech story—and does so with additional dilution and execution risk.

Original filing on SEC EDGAR

More Niki BioSolutions, Inc. news

Niki BioSolutions ATM financing opens $1.396M dilution line | NIKI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.